Zobrazeno 1 - 10 of 233 pro vyhledávání: '"Ronald Paquette"'
3
Akademický článek
Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses
Autor: Srdan Verstovsek, Jason Gotlib, Ruben A. Mesa, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, Francisco Cervantes, Claire N. Harrison, Ronald Paquette, William Sun, Ahmad Naim, Peter Langmuir, Tuochuan Dong, Prashanth Gopalakrishna, Vikas Gupta
Publikováno v: Journal of Hematology & Oncology, Vol 10, Iss 1, Pp 1-6 (2017)
Abstract Background Myelofibrosis (MF) is associated with a variety of burdensome symptoms and reduced survival compared with age-/sex-matched controls. This analysis evaluated the long-term survival benefit with ruxolitinib, a Janus kinase (JAK)1/JA
Externí odkaz: https://doaj.org/article/a557bf1b323a452785b5afc1067a7d10
Zobrazit plný text záznamu
4
Akademický článek
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
Autor: Srdan Verstovsek, Ruben A. Mesa, Jason Gotlib, Vikas Gupta, John F. DiPersio, John V. Catalano, Michael W. N. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, Elliott F. Winton, Jimmie H. Harvey, Murat O. Arcasoy, Elizabeth O. Hexner, Roger M. Lyons, Ronald Paquette, Azra Raza, Mark Jones, Deanna Kornacki, Kang Sun, Hagop Kantarjian, for the COMFORT-I investigators
Publikováno v: Journal of Hematology & Oncology, Vol 10, Iss 1, Pp 1-14 (2017)
Abstract Background The randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial evaluated the JAK1/JAK2 inhibitor ruxolitinib in patients with intermediate-2/high-risk myelofibrosis. The primary and planned 3-year analyses of COMFORT-I
Externí odkaz: https://doaj.org/article/7414efd9cbe24affac81f3167f71f9d0
Zobrazit plný text záznamu
8
Akademický článek
Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis
Autor: John O. Mascarenhas, Moshe Talpaz, Vikas Gupta, Lynda M. Foltz, Michael R. Savona, Ronald Paquette, A. Robert Turner, Paul Coughlin, Elliott Winton, Timothy C. Burn, Peter O’Neill, Jason Clark, Deborah Hunter, Albert Assad, Ronald Hoffman, Srdan Verstovsek
Publikováno v: Haematologica, Vol 102, Iss 2 (2017)
Combined Janus kinase 1 (JAK1) and JAK2 inhibition therapy effectively reduces splenomegaly and symptom burden related to myelofibrosis but is associated with dose-dependent anemia and thrombocytopenia. In this open-label phase II study, we evaluated
Externí odkaz: https://doaj.org/article/99bd5018553941edb2fd816ac116e3c2
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje